Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2B | P63146 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 5/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | CASP6 | P55212 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12847417 | 0.75 | L3MBTL1 (0.71) | UBE2BNPC1RAB9AL3MBTL1SMN1; SMN2 | |
| SCHEMBL27294394 | 0.74 | UBE2B (0.58) | UBE2BNPC1RAB9AL3MBTL1SMN1; SMN2 | |
| SCHEMBL13225628 | 0.72 | SMN1; SMN2 (0.88) | NPC1RAB9AL3MBTL1SMN1; SMN2CASP6 | |
| SCHEMBL523154 | 0.71 | KMT2A (0.67) | NPC1RAB9AMAPTHTTKMT2A | |
| SCHEMBL21645600 | 0.71 | CGAS (0.55) | UBE2BRAB9ASMN1; SMN2MAPTHTT | |
| SCHEMBL31691209 | 0.70 | MAPT (0.61) | UBE2BNPC1RAB9AL3MBTL1SMN1; SMN2 | |
| SCHEMBL8358751 | 0.69 | KMT2A (0.67) | NPC1RAB9AL3MBTL1HTTKMT2A | |
| SCHEMBL2493403 | 0.69 | NPC1 (1.00) | NPC1RAB9AL3MBTL1SMN1; SMN2MAPT | |
| SCHEMBL7533984 | 0.68 | CCNB2 (0.64) | UBE2BRAB9AL3MBTL1MAPTHTT | |
| SCHEMBL21891720 | 0.68 | UBE2B (0.52) | UBE2BNPC1RAB9AL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617905-B2 | Crosslinked alginic acid | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2026-05-05 | — | — | US | claimed |
| US-20240316248-A1 | TRANSPLANTATION DEVICE USING CHEMICALLY CROSSLINKED ALGINIC ACID | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2024-09-26 | — | — | US | claimed |
| CN-116375754-B | Boron-nitrogen compound and organic electroluminescent device | 季华实验室 | 2023-09-12 | — | — | CN | claimed |
| US-20230035986-A1 | NOVEL CROSSLINKED ALGINIC ACID | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2023-02-02 | — | — | US | claimed |
| US-12617905-B2 | Crosslinked alginic acid | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2026-05-05 | — | — | US | disclosed |
| US-12559475-B2 | Tetrazine compound capable of having rapid cycloaddition reaction with non-strained olefinic boronic acid and biomedical application thereof | NANJING UNIVERSITY (CN) | 2026-02-24 | — | — | US | disclosed |
| US-12441713-B2 | Organic compound and organic electroluminescent device comprising the same | SOLUS ADVANCED MATERIALS CO., LTD. (KR) | 2025-10-14 | — | — | US | disclosed |
| US-20250250250-A1 | TETRAZINE COMPOUND CAPABLE OF HAVING RAPID CYCLOADDITION REACTION WITH NON-STRAINED OLEFINIC BORONIC ACID AND BIOMEDICAL APPLICATION THEREOF | NANJING UNIVERSITY (CN) | 2025-08-07 | — | — | US | disclosed |
| CN-119925624-A | Liver targeting compound and conjugate, preparation method and application thereof | 上海数因信科智能科技有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-118973983-A | Sintered body | 东曹株式会社 | 2024-11-15 | — | — | CN | disclosed |
| US-20240342340-A1 | MULTILAYER STRUCTURE USING CHEMICALLY CROSSLINKED ALGINIC ACID | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2024-10-17 | — | — | US | disclosed |
| US-20240316248-A1 | TRANSPLANTATION DEVICE USING CHEMICALLY CROSSLINKED ALGINIC ACID | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2024-09-26 | — | — | US | disclosed |
| CN-113166107-B | Organic compound and organic electroluminescent element comprising same | 索路思高新材料有限公司 | 2024-04-23 | — | — | CN | disclosed |
| CN-114671851-B | Naphthalimide-tetrazine compound and preparation method and application thereof | 中国医学科学院药物研究所 | 2024-03-26 | — | — | CN | disclosed |
| CN-116444451-A | Water-soluble tetrazine and tetrazine membrane probe, and preparation method and application thereof | 四川大学华西医院 | 2023-07-18 | — | — | CN | disclosed |
| US-20230035986-A1 | NOVEL CROSSLINKED ALGINIC ACID | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2023-02-02 | — | — | US | disclosed |
| CN-114671851-A | Naphthalimide-tetrazine compound and preparation method and application thereof | 中国医学科学院药物研究所 | 2022-06-28 | — | — | CN | disclosed |
| US-20220077400-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | SOLUS ADVANCED MATERIALS CO., LTD. (KR) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559475-B2 | Tetrazine compound capable of having rapid cycloaddition reaction with non-strained olefinic boronic acid and biomedical application thereof | ERBB2, SLC7A1, BCL6 | UBE2B 1178/4885NPC1 973/4885RAB9A 1338/4885 |
| US-20220077400-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | ELAVL1, VDAC1, ELAVL3 | UBE2B 1579/4885NPC1 833/4885RAB9A 1572/4885 |
| US-20250250250-A1 | TETRAZINE COMPOUND CAPABLE OF HAVING RAPID CYCLOADDITION REACTION WITH NON-STRAINED OLEFINIC BORONIC ACID AND BIOMEDICAL APPLICATION THEREOF | TBCA, BTD, TBC1D15 | UBE2B 943/4885NPC1 2070/4885RAB9A 1967/4885 |
| US-12441713-B2 | Organic compound and organic electroluminescent device comprising the same | ELAVL1, VDAC1, ELAVL3 | UBE2B 1579/4885NPC1 833/4885RAB9A 1572/4885 |
| US-12617905-B2 | Crosslinked alginic acid | ALG1, ANXA6, HEXB | UBE2B 229/4885NPC1 4601/4885RAB9A 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.